Ovid Therapeutics Inc.
OVID· Nasdaq
Released Nov 12, 2020, after the close
10-Q filed Nov 13, 2020, 44 days after period end · 0001564590-20-053666
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $6.91M | — | — | — |
| Net Income | -$16.42M | -$16.63M | -$12.96M | -$9.36M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$0.28 |
| -$0.43 |
| -$0.53 |
| -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.